Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYOC29)

• Drug Name: Hirudin Drug Info
• Synonyms: Hirudin (53-64); 135546-61-1; Hirudin 53-64; DTXSID20159463; L-Alanine, L-asparaginylglycyl-L-alpha-aspartyl-L-pheylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucyl-
• Cross-matching ID:
  PubChem CID: 72941487
  CAS Number: CAS 8001-27-2
  TTD Drug ID: DMYOC29

Molecule-Related Drug Atlas

Drug(s) Targeting Coagulation factor IIa (F2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Argatroban	DMFI46A	Thrombosis	DB61-GB90	Approved	[3]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[4]
Bivalirudin	DMECRX1	Thrombocytopenia	3B64	Approved	[5]
Ximelegatran	DMU8ANS	Myocardial infarction	BA41-BA43	Approved	[6]
Dabigatran	DMDI6R4	Stroke	8B20	Approved	[7]
Desirudin Recombinant	DM2BTFN	Coagulation defect	3B10.0	Approved	[8]
Human prothrombin complex concentrate	DMPHVQ1	Bleeding disorder	GA20-GA21	Approved	[9]
Lepirudin	DM1I3D5	Thrombocytopenia	3B64	Approved	[10]
Anisindione	DM2C48U	Coagulation defect	3B10.0	Approved	[11]
ATryn antithrombin	DM79Y2T	Multiple sclerosis	8A40	Approved	[12]

Drug(s) Affected By Myeloperoxidase (MPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[13]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[14]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[13]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[13]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[15]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[16]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[17]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[18]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Propylthiouracil	DM6D7N8	Hyperthyroidism	5A02	Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor IIa (F2)	TT6L509	THRB_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Myeloperoxidase (MPO)	OTOOXLIN	PERM_HUMAN	Gene/Protein Processing	[2]

References

• [1] Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 2002 Nov 19;41(46):13556-69.
• [2] Thrombin inhibits the anti-myeloperoxidase and ferroxidase functions of ceruloplasmin: relevance in rheumatoid arthritis. Free Radic Biol Med. 2015 Sep;86:279-94.
• [3] Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
• [4] New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
• [5] New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
• [6] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [7] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
• [10] Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
• [11] Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
• [12] Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.
• [13] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [14] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [15] An evaluation of myeloperoxidase-mediated bio-activation of NSAIDs in promyelocytic leukemia (HL-60) cells for potential cytotoxic selectivity. Toxicol Lett. 2017 Oct 5;280:48-56.
• [16] Differentiation between stoichiometric and anticatalytic antioxidant properties of benzoic acid analogues: a structure/redox potential relationship study. Chem Biol Interact. 2013 Nov 25;206(2):194-203.
• [17] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [18] Effect of anti-rheumatic drugs on the release of lysosomal enzymes from human leukocytes. Z Rheumatol. 1984 Jan-Feb;43(1):23-6.
• [19] Benzodithiophenes induce differentiation and apoptosis in human leukemia cells. Cancer Res. 2005 Sep 1;65(17):7847-55. doi: 10.1158/0008-5472.CAN-05-1053.
• [20] Inhibition of oxidation activity of myeloperoxidase (MPO) by propylthiouracil (PTU) and anti-MPO antibodies from patients with PTU-induced vasculitis. Clin Immunol. 2007 Feb;122(2):187-93. doi: 10.1016/j.clim.2006.09.011. Epub 2006 Oct 27.